Interval Between Colonoscopies May Be Lengthened For Some Colorectal Cancer Patients, Ochsner Study Concludes

Publication
Article
OncologyONCOLOGY Vol 10 No 8
Volume 10
Issue 8

The interval between follow-up colonoscopies may be increased from 1 to 3 years for colorectal cancer patients whose examinations are negative after 2 years, concludes a study of 389 patients at the Ochsner Clinic, New Orleans, Louisianna,

The interval between follow-up colonoscopies may be increasedfrom 1 to 3 years for colorectal cancer patients whose examinationsare negative after 2 years, concludes a study of 389 patientsat the Ochsner Clinic, New Orleans, Louisianna, reported inDiseases of the Colon & Rectum (DC&R).

"We believe this recommendation outlines appropriate andcost-effective colon surveillance guidelines for colorectal cancerpatients and will help decrease the total number of normal surveillanceexaminations," write Ochnser's Douglas A. Khoury, MD, FrankG. Opelka, MD, David E. Beck, MD, Terry C. Hicks, MD, Alan E.Timmcke, MD, and J. Byron Gathright, Jr., MD.

Current guidelines of the American Society of Colon and RectalSurgeons (ASCRS) recommend annual colonoscopies for up to 5 yearsafter a patient has surgery for colorectal cancer.

Reoperation Plus Surgery for Local Recurrence of Recal Carcinoma

Another study reported in the March issue of DC&R offers increasedhope for patients who experience a local recurrence of cancerafter surgery for rectal cancer. "In selected patients withlocal recurrence of rectal carcinoma, reoperation with irradiationmay result in good palliation and possibly cure," reportTheoWiggers, MD, PhD, Mark R. de Vries, MD, and Bernadette Veeze-Kuypers,MD, of the Departments of Surgical Oncology and Radiotherapy atDr. Daniël den Hoed Cancer Center in Rotterdam, The Netherlands.

Surgery is the most effective treatment for colorectal cancer.Even when all visible cancer has been removed, it is possiblefor cancer cells to be present in other areas of the body. Thechance of recurrence depends on the characteristics of the originalcancer and the effectiveness of chemotherapy or radiation, ifneeded, or other follow-up treatment. Patients with recurrentcancers--if diagnosed early--may benefit, or be cured, by furthersurgery or other treatment.

Related Videos
Increasing screening for younger individuals who are at risk of colorectal cancer may help mitigate the rising early incidence of this disease.
Laparoscopy may reduce the degree of pain or length of hospital stay compared with open surgery for patients with colorectal cancer.
Rahul Gosain, MD; Sam Klempner, MD; and Rohit Gosain, MD, presenting slides
Rahul Gosain, MD; Sam Klempner, MD; and Rohit Gosain, MD, presenting slides
Rahul Gosain, MD; Sam Klempner, MD; and Rohit Gosain, MD, presenting slides
Rahul Gosain, MD; Sam Klempner, MD; and Rohit Gosain, MD, presenting slides
Rahul Gosain, MD; Sam Klempner, MD; and Rohit Gosain, MD, presenting slides
Tailoring neoadjuvant therapy regimens for patients with mismatch repair deficient gastroesophageal cancer represents a future step in terms of research.
Not much is currently known about the factors that may predict pathologic responses to neoadjuvant immunotherapy in this population, says Adrienne Bruce Shannon, MD.
The toxicity profile of tislelizumab also appears to look better compared with chemotherapy in metastatic esophageal squamous cell carcinoma.